With Review and Restructuring Over, Gene Logic Says Molecular Dx New Avenue for Genomics Unit | GenomeWeb
Gene Logic said last week that a recently completed external business review supports the company’s decision to shift its focus from its floundering genomics business and onto its drug-repositioning business.
 
Though the review confirmed that Gene Logic’s potential lies in its drug-repositioning business, the company said it will retain “core competencies” for its genomics products and services and will continue to support existing customers.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.